Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Amgen

Aranesp flat, other drugs pick up slack.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 1Q10

1Q Revenues: $3.5 billion (+9%)

1Q Earnings: $1.2 billion (+14%)

Comments: U.S. sales rose 7% to $2.7 billion, while international sales were up 16% to $851 million, including an 8% boost from currency fluctuations. Aranesp sales were flat at $627 million, including an 8% drop in the U.S. Epogen sales rose 10% to $623 million. Neulasta/Neupogen combined sales rose 10% to $1.2 billion. Enbrel sales were up 6% to $804 million, and Sensipar revenues jumped 21% to $179 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters